Status:
COMPLETED
Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Obesity
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Researchers are doing this study to compare the effects of drugs approved for long-term weight loss combined with an employer-based weight management program with the effects of the weight management ...
Eligibility Criteria
Inclusion
- Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine eligibility for the study
- Male or female, age more than or equal to 18 years at the time of signing informed consent
- Body mass index (BMI) more than or equal 30 kg/m\^2
- Enrolled in Cleveland Clinic Employee Health Plan, and expecting to be covered by the Cleveland Clinic Employee Health Plan for the duration of the study
Exclusion
- Contraindications to all of the medications approved by the FDA for chronic weight management according to the label
- Previous participation in this study. Participation is defined as signed informed consent
- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice)
- Participation in another clinical trial within 30 days before screening
- Treatment with any medication with the intention of weight loss within 90 days before screening
- Previous or current participation in Cleveland Clinic's Integrated Medical Weight Management Program
- History of (or plans during the study period for) bariatric surgery, or use of minimally-invasive weight loss devices (i.e. Intragastric balloons, lap bands) not removed within 1 year prior to screening
- History of type 1 or type 2 diabetes mellitus
- Hemoglobin A1c (HbA1c) more than or equal to 6.5% at screening or within 90 days prior to randomization
- Any condition, unwillingness or inability, not covered by any of the other exclusion criteria, which, in the study clinician's opinion, might jeopardize the subject's safety or compliance with the protocol
Key Trial Info
Start Date :
January 7 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 22 2020
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03799198
Start Date
January 7 2019
End Date
May 22 2020
Last Update
November 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Cleveland, Ohio, United States, 44195